Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and tolerability of sorafenib as second
line treatment in patients with Advanced or Metastatic Gastric Cancer (A/MGC).